US EditionPublished • loading... • Updated
Signadori Bio Appoints Dr Selwyn Ho as CEO to Drive Company Growth
Summary by World Business Outlook
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Signadori Bio appoints Dr Selwyn Ho as CEO to drive company growth
Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours, recently announced the appointment of Dr. Selwyn Ho as Chief Executive Officer. Dr. Ho is an experienced biopharma and biotech executive, with nearly 30 years of experience across commercialisation, drug development and multiple pre-& post-product launches, with a fo…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
